US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by SPR Therapeutics, Inc.

News headline image
SPRINT® PNS System Now Covered Nationally by Aetna®
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
Predictors of Success for 60-Day Peripheral Nerve Stimulation (PNS) Used for Treatment of Chronic Shoulder Pain: A Multi-Center Retrospective Chart Review
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Announces Eight Featured Posters and Presentations at NANS 2026
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Reaches Milestone 50,000th Implant of the SPR® SPRINT® PNS System
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
The American Society of Pain and Neuroscience (ASPN) Issues Consensus Guidelines on Peripheral Nerve Stimulation
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
Four SPR® Abstracts Honored with Awards at 24th Annual ASRA Pain Meeting
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
RESET™ Clinical Trial Demonstrates Superior Pain Relief with SPRINT® PNS Compared to Standard Interventional Management for Chronic Low Back Pain
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR to Feature Five Abstracts on SPRINT® PNS at ASPN 2025
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
The American Society of Pain and Neuroscience (ASPN) Publishes Consensus Guidelines for the Use of 60-Day Peripheral Nerve Stimulation (PNS) Therapy, Highlighting Strong Clinical Applications for SPR® SPRINT® PNS
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Receives Fourth Consecutive Northeast Ohio Top Workplaces Award
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Announces Publication of Sustained Chronic Shoulder Pain Outcomes Up to Five Years Post-Treatment
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPRINT® PNS Meets Primary Endpoint of Reduction in Head Pain in First Publication of Multicenter Prospective MONARCH™ Study
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Expands Access to the SPRINT® PNS System for Veterans with New Distribution Agreement with Veteran’s Health Medical Supply
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Announces Presentation of Four Abstracts Featuring the SPRINT® PNS System at NANS 2025
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR® Therapeutics Debuts New SPRINT® PNS Data for Low Back, Shoulder, Knee, and Headache at the 23rd Annual ASRA Pain Medicine Meeting
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPRINT® PNS Demonstrates Robust Results in Addressing Chronic Shoulder Pain
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
From SPR Therapeutics, Inc.
Via GlobeNewswire
Tickers SLRC
News headline image
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Therapeutics Announces 20,000th Patient Implant of SPRINT® PNS System
From SPR Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPR Therapeutics Named a Top Workplace for Second Consecutive Year
From SPR Therapeutics, Inc.
Via GlobeNewswire